Skip to main content
[Preprint]. 2022 Nov 28:2022.11.27.518117. [Version 1] doi: 10.1101/2022.11.27.518117

Figure 3. Vaccine-elicited immune sera protection against SARS-CoV-2 WA1/2020 N501/D614G infection in wild-type, FcγR I KO, FcγR II KO, FcγR III KO, and FcγR I/III/IV KO mice.

Figure 3.

(a) Scheme of passive transfer, virus challenge, and tissue harvest. (b) Neutralizing antibody response against SARS-CoV-2 WA1/2020 N501Y/D614G using sera from naïve (circles) or Wuhan-1 spike protein vaccinated (squares) mice. Also shown is serum neutralizing antibody activity from recipient wild-type (black squares) and FcγR I/III/IV KO (green squares) mice one day after transfer of immune sera. (c-g) Twelve-week-old male wild-type, FcγR I KO, FcγR II KO, FcγR III KO, and FcγR I/III/IV KO mice were passively transferred by intraperitoneal injection 60 μL of naïve or vaccine-immune sera one day before intranasal challenge with 104 FFU of WA1/2020 N501Y/D614G. At 4 dpi, viral RNA and infectious virus was measured in the upper respiratory tract (nasal wash) (c), nasal turbinates (d-e)) or lungs (f-g) and quantified by qRT-PCR and plaque assay. Panels c-e: wild-type mice only; panels f-g: wild-type, FcγR I KO, FcγR II KO, FcγR III KO, and FcγR I/III/IV KO mice (bars indicate median; n = 9–18 mice per group, three experiments, dotted lines show LOD). One-way ANOVA with Tukey’s post-test (ns, not significant; ***P < 0.01, **P < 0.001, ****P < 0.0001).